Entry Rationale
Entry was considered after confirming news of the upgraded sales outlook and the current price position between the 20-day resistance level of $73.43 and the support level of $61.19.
CareDx raises 2026 revenue outlook to $520M-$530M as it plans AlloHeme launch in Q1 2027
CareDx raised its full-year 2026 revenue guidance from $520 million to $530 million, in line with its plan to launch AlloHeme in the first quarter of 2027.
Entry was considered after confirming news of the upgraded sales outlook and the current price position between the 20-day resistance level of $73.43 and the support level of $61.19.
At the current price, if it reaches the 20-day resistance level of $73.43, I will take profit; in the event of a decline, if the 20-day low support level of $61.19 is broken, I will cut losses.
RSI(14) is at 69.3, nearing the overbought zone, the moving averages are in a bullish alignment, trading volume is 1.25 times the 20-day average, and the 7-day volatility (rate of change) recorded +3.4%.
In past historical data, this stock has shown a mixed pattern around events, such as -1.3% on 2026-08-03, +9.5% on 2026-07-31, -3.0% on 2026-07-17, -1.5% on 2026-07-16, and +2.4% on 2026-07-06.
The forecasted return was 2.5%, but the actual result recorded an 'OVERHIT' rating of 22.2%, showing an upward surge that significantly exceeded expectations. At the time of entry, a conservative target return of 2.5% was set due to the positioning near the overbought zone with an RSI (14) of 69.3 and around the 20-day resistance line ($73.43), but coupled with an increasing trend in thematic news, the actual price surged much more strongly.
Through this trade, I learned that when supported by a rising trend in theme news volume and an S-Class conversion rate, we should maintain the flexibility to leave room for trend extension rather than strictly viewing resistance levels as mere upper bounds. In the next trade, I will consider setting wider profit-taking targets during phases of strong theme momentum.